Status:

RECRUITING

Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma

Lead Sponsor:

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Conditions:

Perihilar Cholangiocarcinoma

Klatskin Tumor

Eligibility:

All Genders

18-70 years

Brief Summary

This is multicentric, single-arm, observational, investigator-drive study investigating the efficacy of liver transplantation after successful downstaging/disease control of unresectable perihilar cho...

Detailed Description

Patients with unresectable pCCA who fit within inclusion criteria will be enrolled in the study. They will undergo staging laparoscopy with nodal sampling at the hepatic hilum. In case of negative sta...

Eligibility Criteria

Inclusion

  • Diagnosis of unresectable peripheral cholangiocarcinoma arising one centimeter or more above the superior pancreatic margin, with tumor diameter ≤ 3 cm, diagnosed by:
  • Transcatheter biopsy or brush cytology
  • CA-19.9 \> 100 mg/ml and/or a mass on cross-sectional imaging with a malignant appearing stricture on cholangiography
  • Biliary ploidy by FISH with a malignant appearing stricture on cholangiography
  • Age between 18 years and 70 years
  • Absence of intra- and extrahepatic metastases
  • Absence of lymph-nodal metastases at any site
  • Biliary stenting of all liver districts
  • No contraindications to liver transplantation
  • No concomitant malignancies or history of other malignancies in the previous 5 years
  • Written informed consent

Exclusion

  • Intrahepatic cholangiocarcinoma
  • Uncontrolled infection
  • Concomitant malignancies or history of other malignancies in the previous 5 years

Key Trial Info

Start Date :

June 1 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

January 1 2030

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT06986486

Start Date

June 1 2025

End Date

January 1 2030

Last Update

May 23 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fondazione IRCCS Istituto Nazionale Tumori di Milano

Milan, Michigan, Italy, 20133